Narcolepsy with cataplexy
Central nervous system
Sodium oxybate is not recommended for use as a treatment of narcolepsy with cataplexy. The evidence demonstrates sodium oxybate’s efficacy when used for the treatment of narcolepsy with cataplexy. There are however significant concerns, as follows:
• The only UK based cost effectiveness estimate, which was provided by the SMC, estimated sodium oxybate’s cost per QALY to be between £49,590 and £65,980. These figures and concerns that the potential costs of adverse events are not included in the costing model and that the clinical resource savings may not be realised, led the SMC to conclude that the drug was not cost effective.
• Safety issues and side effects, particularly respiratory depression are significant
• Sodium oxybate is a schedule 2 Controlled Drug with an abuse potential
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria